Insights+: The US FDA New Drug Approvals in July 2020

The US FDA has approved multiple NDAs and BLAs in July 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 59 novel products so far in 2020, including 8 in July 2020. Additionally,…

BySenior EditorAugust 27, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in June 2020

The US FDA has approved multiple NDAs and BLAs in Jun 2020, leading to treatments for patients and advances in the health care industry. The Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 51 novel products so far in 2020, including 8 in Jun 2020. Additionally,…

BySenior EditorJuly 24, 2020

EVENTS

20th International Nutrition & Diagnostics Conference 2020

INDC 2020, Congress Centre Masarykova kolej, Prague, Nov 29 'Dec 02, 2020INDC is an international forum for a scientific discussion focused on the understanding the relationship between nutrition and clinical diagnostics.TOPICS:METABOLOMICS AND MICROBIOME, PROBIOTICS, PREBIOTICS, NUTRACEUTICALS AND BOTANICALS FOR HUMAN HEALTHProbiotics and Prebiotics, Microbiota, Polyphenols, Bioactive Compounds, Prediction of Bioavailability, Chronic Diseases,…

BySenior EditorJuly 14, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of June 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potencyMylan with its partners Lupin and Biocon received MAA for Nepexto (biosimilar, etanercept) in EU and the US FDA's Approval for Semglee (biosimilar, insulin glargine) respectivelyOur team at PharmaShots has summarized 15 key events of the…

BySenior EditorJuly 3, 2020

THOUGHTSPOT

Virtual Clinical Trials – Are They the Future of India?

2020 is a year that nobody ever thought could turn their lives upside down. The beginning of this year witnessed the worldwide onset of Coronavirus disease or COVID-19 that has till now infected millions of people around the globe killing tens of thousands. In March 2020, WHO declared it to be a pandemic. There has…

BySenior EditorJune 25, 2020

INSIGHTS+

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

The American Society of Clinical Oncology (ASCO) is a platform for cancer experts to share views on the latest advancements and new approaches in cancer research and was held virtually this year due to the COVID-19 pandemicJanssen highlights its oncology portfolio, Merck & Pfizer demonstrated the potential of Bavencio in GTT while AstraZeneca showcased…

BySenior EditorJune 1, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March and April 2020

The US FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products so far in 2019.However, there is a significant increase in multiple diseases while the new approvals are helping and advancing the changes to understand, diagnose, and treat the diseasesOur team…

BySenior EditorMay 15, 2020

INSIGHTS+

Insights+ Key Biosimilars Events of April 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a 'reference…

BySenior EditorMay 8, 2020

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2020

The first quarter of 2020 includes big news regarding global companies. The highlight of the quarter is the acquisition of QIAGEN by ThermoFisher for ~$11.5B, Danaher's acquisition of the biopharma business of GE Life Sciences in an all-cash transaction for ~$21.4B. Numerous alliances are there which include Fosun's agreement with BioNTech to develop and commercialize…

BySenior EditorApril 8, 2020

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2020

The US FDA has approved multiple NDAs and BLAs in Feb 2020, leading to treatments for patients and advances in health careThe Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 13 novel products so far in 2020, including 10 in Feb and 3 in Jan…

BySenior EditorMarch 27, 2020

Insights+: The US FDA New Drug Approvals in July 2020

Insights+: The US FDA New Drug Approvals in June 2020

20th International Nutrition & Diagnostics Conference 2020

Insights+ Key Biosimilars Events of June 2020

Virtual Clinical Trials – Are They the Future of India?

Insights+: Key Events of ASCO 2020 Virtual Annual Meeting #ASCO20

Insights+: The US FDA New Drug Approvals in March and April 2020

Insights+ Key Biosimilars Events of April 2020

PharmaShots’ Key Highlights of First Quarter 2020

Insights+: The US FDA New Drug Approvals in February 2020

Contact US

OUR INFORMATION

FOLLOW US